623 related articles for article (PubMed ID: 21875498)
1. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
[TBL] [Abstract][Full Text] [Related]
3. mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease.
Derer S; Till A; Haesler R; Sina C; Grabe N; Jung S; Nikolaus S; Kuehbacher T; Groetzinger J; Rose-John S; Rosenstiel PC; Schreiber S
Gut; 2013 Mar; 62(3):376-86. PubMed ID: 22535372
[TBL] [Abstract][Full Text] [Related]
4. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
[TBL] [Abstract][Full Text] [Related]
8. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
Ueda N; Tsukamoto H; Mitoma H; Ayano M; Tanaka A; Ohta S; Inoue Y; Arinobu Y; Niiro H; Akashi K; Horiuchi T
Inflamm Bowel Dis; 2013 May; 19(6):1224-31. PubMed ID: 23619715
[TBL] [Abstract][Full Text] [Related]
13. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
[TBL] [Abstract][Full Text] [Related]
14. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
15. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
[TBL] [Abstract][Full Text] [Related]
17. TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease.
Werner L; Berndt U; Paclik D; Danese S; Schirbel A; Sturm A
Gut; 2012 Jul; 61(7):1016-27. PubMed ID: 22068169
[TBL] [Abstract][Full Text] [Related]
18. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis.
Dayer Schneider J; Seibold I; Saxer-Sekulic N; Paredes BE; Saurer L; Mueller C
Eur J Immunol; 2009 Jul; 39(7):1743-53. PubMed ID: 19551899
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis as a therapeutic tool in IBD?
Lügering A; Lebiedz P; Koch S; Kucharzik T
Ann N Y Acad Sci; 2006 Aug; 1072():62-77. PubMed ID: 17057191
[TBL] [Abstract][Full Text] [Related]
20. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.
Wojtal KA; Rogler G; Scharl M; Biedermann L; Frei P; Fried M; Weber A; Eloranta JJ; Kullak-Ublick GA; Vavricka SR
PLoS One; 2012; 7(8):e43361. PubMed ID: 22937039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
